Fluvastatin Sodium

CHEMBL2218894 Phase 4 Approved Small molecule
Half-Life
Bioavailability
Protein Binding
Molecular Weight
433.4 g/mol
LogP
Phase
4

This sodium salt form of fluvastatin is a statin medication used to lower elevated blood cholesterol levels and reduce the risk of heart attack and stroke. It works by inhibiting the key enzyme in the liver's cholesterol synthesis pathway.

Molecular Weight

433.4000 g/mol

TPSA

85.50 Ų

Therapeutic Areas

Mechanism of Action

Competitively inhibits HMG-CoA reductase, the rate-limiting enzyme in the mevalonate pathway of cholesterol biosynthesis. This reduces intracellular cholesterol, upregulates LDL receptor expression, and lowers circulating LDL cholesterol.

Pharmacokinetics (PK)

Pharmacodynamics (PD)

Mechanism

Competitively inhibits HMG-CoA reductase, the rate-limiting enzyme in the mevalonate pathway of cholesterol biosynthesis. This reduces intracellular cholesterol, upregulates LDL receptor expression, and lowers circulating LDL cholesterol.

2D Structure

SVG PNG

Cite this structure


                        

Embed this structure


                        

SMILES

CC(C)n1c(/C=C/C(O)CC(O)CC(=O)[O-])c(-c2ccc(F)cc2)c2ccccc21.[Na+]

InChI

InChI=1S/C24H26FNO4.Na/c1-15(2)26-21-6-4-3-5-20(21)24(16-7-9-17(25)10-8-16)22(26)12-11-18(27)13-19(28)14-23(29)30;/h3-12,15,18-19,27-28H,13-14H2,1-2H3,(H,29,30);/q;+1/p-1/b12-11+;

Molecular Formula

C24H25FNNaO4

HBD / HBA

2 / 5

Rotatable Bonds

8

Heavy Atoms

31

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

Frequently Asked Questions

This sodium salt form of fluvastatin is a statin medication used to lower elevated blood cholesterol levels and reduce the risk of heart attack and stroke. It works by inhibiting the key enzyme in the liver's cholesterol synthesis pathway.

Competitively inhibits HMG-CoA reductase, the rate-limiting enzyme in the mevalonate pathway of cholesterol biosynthesis. This reduces intracellular cholesterol, upregulates LDL receptor expression, and lowers circulating LDL cholesterol.

Yes, Fluvastatin Sodium is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

  • ChEMBL — European Bioinformatics Institute (EBI). CHEMBL2218894. Open-access bioactivity database.
  • PubChem — National Center for Biotechnology Information (NCBI). CID 23679527. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.

Medical Disclaimer

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.